Instrument Inactif

Communiqués XOMA Royalty Corporation NYSE

Actions

XOMAP

US98419J3059

Production de spectacles

Temps Différé NYSE 22:30:00 13/07/2026			Varia. 5j.	Varia. 1 janv.
24,98 ^USD	+0,04%		-.--%	-7,03%

14/07	Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) a finalisé l'acquisition de XOMA Royalty Corporation (NasdaqGM:XOMA) auprès d'un groupe d'actionnaires.	CI
14/07	Ligand Pharmaceuticals finalise l'acquisition de XOMA Royalty pour 739 millions de dollars	MT

Communiqués

14/07	XOMA Royalty : Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date	PU
12/06	XOMA Royalty : Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator	PU
12/06	XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date	AQ
28/04	XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA	BU
27/04	Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator	AQ
18/03	XOMA Royalty Declares Quarterly Preferred Stock Dividends	AQ
18/03	XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements	AQ
12/03	XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026	AQ
18/02	XOMA Royalty to Present at Investor Conferences in March	AQ
09/02	XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.	AQ
12/01	XOMA Royalty Announces CFO Transition	AQ
30/12	XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab	AQ
22/12	XOMA Royalty Declares Quarterly Preferred Stock Dividends	AQ
05/12	XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc	AQ
21/11	XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.	AQ
12/11	XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements	AQ
17/10/25	XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement	AQ
02/10/25	XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.	AQ
24/09/25	ESSA Pharma Inc. Amends Agreement with XenoTherapeutics	PR
22/09/25	XOMA Royalty Declares Quarterly Preferred Stock Dividends	AQ
17/09/25	XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.	AQ
03/09/25	XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference	AQ
14/08/25	XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements	AQ
13/08/25	XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements	AQ
11/08/25	XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics	AQ